Figure 5.

AZD-0530 treatment prevents cigarette smoke–induced MAPK activation, c-Src, activity and EGFR phosphorylation. A/J mice were exposed to 2 months of cigarette smoke or room air in combination with daily oral administration of vehicle or AZD-0530. (A) Immunoblots for c-Src, c-Raf, and MAPK phosphorylation were conducted on the lung tissue lysate protein from these mice, and densitometry analysis was performed. c-Src activity (B) and gene expression (C) were measured in the lungs tissue of the mice. (D) Immunoblot analysis for p-PKC-α(Thr638), PKC-α, p-EGFR(Thr1068), EGFR, and Actin were performed on lung tissue from the room air and 1-year cigarette smoke–exposed mouse groups. Graphs are represented as mean ± SEM of 10 samples. P values are shown comparing both treatments connected by a line.